Association of the HTR2C-759C/T polymorphism and antipsychotic-induced weight gain: a meta-analysis

Yan Chen, Yewei Wang, Xinyu Fang, Yi Zhang, Lisheng Song, Chen Zhang

ABSTRACT

Background Antipsychotic-induced weight gain (AIWG) is a crucial factor for the medication cessation of patients with schizophrenia. Multiple studies have shown that the functional polymorphism -759C/T (rs3813929) in the HTR2C promoter region could possibly be correlated with AIWG.

Aim To evaluate the genetic association of the HTR2C-759C/T polymorphism and AIWG in patients with schizophrenia with antipsychotic drugs (APDs) administration.

Methods Eligible studies were identified by searching the following databases: PubMed, Embase, Web of Science, China Nation Knowledge Infrastructure (CNKI), VIP, Wanfang Data, Chinese Biomedical Literature Database (CBM) and the Airiti Library. The quality of studies was evaluated based on the Newcastle-Ottawa Scale. The pooled OR and 95% CI were calculated for the dominant (CT/TT/T vs CC/C) mode, and subgroup analyses were performed based on ethnicity, antipsychotic medication and gender; all statistical analyses were performed using the statistical software STATA V.12.0.

Result A total of 17 studies with 3170 patients with schizophrenia were included in our meta-analysis. The result of the meta-analysis has shown that the association between the -759C/T polymorphism and AIWG is statistically significant (OR 0.34, 95% CI: 0.20 to 0.57, z=4.11, p<0.001). The subgroup analyses revealed significant correlations between the -759C/T polymorphism and AIWG in the Caucasian population (OR 0.33, 95% CI: 0.14 to 0.77, z=2.55, p=0.011), the Asian population (OR 0.31, 95% CI: 0.18 to 0.52, z=4.46, p<0.001), the patients with APDs administration (CT/TT/T vs CC/C: OR 0.63, 95% CI: 0.40 to 1.00, z=1.97, p=0.049) and the patients with atypical antipsychotic drug administration (CT/TT/T vs CC/C: OR 0.21, 95% CI: 0.09 to 0.47, z=3.83, p<0.001). The sensitivity analysis showed that the results were stable. Beggs’s test (after correction z=1.07, p=0.287) and Egger’s test (t =−2.41, p=0.029) show that the included articles have no significant publication bias.

Conclusion There is a significant genetic association between HTR2C-759C/T and AIWG, and patients with T allele are less likely to have AIWG.

INTRODUCTION

Schizophrenia is a highly prevalent complex neuropsychiatric disease, and the pathophysiology is yet to be fully elucidated. Antipsychotic drugs (APDs) are the primary treatment methods for schizophrenia. Nevertheless, antipsychotic-induced weight gain (AIWG), a serious side effect, leads to increased risk for cardiovascular morbidity and social withdrawal and therefore is a crucial factor for the cessation of medication. 1 2

The variability of AIWG among inter-racial and inter-individual along with the results of twin and adoption studies had suggested that the genetic factor plays an important role in AIWG. The gene of 5-hydroxytryptamine 2C receptor (5-HT2CR), HTR2C, is located at chromosome Xq23, and its expression product 5-HT2CR has a role in the mechanism of antipsychotic medication. Furthermore, atypical antipsychotic drugs (AAPs) that are prone to induce AIWG have a better affinity to 5-HT2CR than typical antipsychotic drugs (TAPs). 3 Numerous studies have consistently pinpointed that the changes of the serotonin system have a great effect on food and body weight regulation. High activity of 5-HT2CR decreases the appetite of mice, whereas the antagonists have an opposite effect. Furthermore, 5-HT2CR-deficient mice adopted an abnormal control of feeding behaviour, resulting in obesity and hyperglycaemia. 4–6 Taken together, previous genetic studies have found that a constellation of single-nucleotide polymorphisms in HTR2C is related to AIWG; the relationship between the -759 C/T (rs3813929) polymorphism and AIWG is an active field of research, but the results are controversial. Two earlier meta-analyses 7 8 ignored a number of studies in China; therefore, we performed a meta-analysis applying both English and Chinese databases to assess whether HTR2C-759C/T is associated with AIWG.
METHODS

Search strategy

A literature search of English (PubMed, Embase, Web of Science) and Chinese (China Nation Knowledge Infrastructure (CNKI), Wanfang Data, VIP, Chinese Biomedical Literature Database (CBM), the Airiti Library) databases was conducted for eligible articles published up until 31 December 2018, using key words “Weight gains”, “schizophrenia”, “polymorphism” and “HTR2C”.

Inclusion and exclusion criteria

Studies were selected according to the following criteria presented using the acronym, PICOS: Participants (P): adult patients diagnosed with schizophrenia based on the Diagnostic and Statistical Manual of Disorder (DSM), International Statistical Classification of Diseases and Related Health Problems (ICD) or Chinese Classification of Mental Disorders (CCMD), while the HTR2C -759C/T polymorphism was genotyped. Intervention (I): administration with antipsychotics. Comparison (C): patients with AIWG or not. Outcomes (O): the primary outcome included genotype frequencies, and the number or proportion of patients with weight gain in each genotype group. Study design (S): Case-control studies and cohort studies with meta-analyzable data.

Studies were excluded according to the following criteria: (1) animal experiments; (2) patients enrolled had organic brain disease or were in medical conditions that could affect the weight (ie, hyperthyroidism, diabetes, etc); (3) studies with errors or incomplete data; (4) not published in Chinese or English languages; (5) only select the most complete study if a repeated publication or an overlapping sample existed.

Assessment of study quality and data extraction

According to the Newcastle-Ottawa Scale (NOS), the quality of the included literature was evaluated based on three aspects: the selection of the research population (full score of 4), the comparability between groups (full score of 2) and the measurement of exposure factors (full score of 3), with a total score of 9 points.

The following data were extracted: study population characteristics (ie, country, population, gender, age, diagnosis), sample size, prior antipsychotic medication, type of antipsychotic medication, duration of treatment, definition of weight gain, conclusions and NOS score. Genotype and allele frequencies were calculated if not given directly in the articles.

Quality evaluation and data extraction were completed by two researchers (YC and Y-WW) independently. Inconsistent opinion was resolved by discussion or assistance from a third researcher (XYF).

Statistical methods

The presence of AIWG was analysed as a binary variable, which was defined by the original diagnostic definition applied in each study. The relationship between the HTR2C -759C/T polymorphism and AIWG in patients with schizophrenia was measured by using OR and 95% CI. In addition, multiple studies demonstrated that the T allele has a dominant effect, indicating that it is more difficult for patients with the T allele (CT/TT/T) to suffer from AIWG than the homozygous wild type (CC/C). Therefore, we applied the dominant mode (CT/TT/T vs CC/C) to calculate ORs and 95% CI.

Heterogeneity was assessed using the I² test–based Cochran Q test. The quantification of heterogeneity was evaluated using an I² index that approximately had values from 0% to 100%.

According to the Cochrane Handbook for Systematic Reviews of Interventions, if I² <40%, it can be considered that the heterogeneity of the included literature is not important; 30%–60% may be considered to have moderate heterogeneity; 50%–90% may be considered to have substantial heterogeneity; 75%–100% may have considerable heterogeneity. If p value >0.10 or I² <50%, the fixed-effect model (Mantel-Haenszel) was used to pool the data from included studies. Otherwise, the random-effect model (DerSimonian-Laird) was performed. We used Z test to assess the statistical significance of the pooled ORs. Meta-regression was performed to detect the source of heterogeneity.

Publication bias was detected by using Begg’s funnel plot and Egger’s regression test in the meta-analysis; a p value <0.01 indicates the existence of significant publication bias. Other than the tests for heterogeneity and publication bias, all analyses were two tailed, and the level of significance was set at 0.05.

All statistical analyses were performed using STATA V.12.0 (Stata, College Station, TX, USA).
### Table 1 Characteristics of the eligible studies

| Studies         | Country          | Ethnicity | Sample size | Male/female | Average age (SD) | Types of diagnosis | Prior antipsychotic medication | Type of antipsychotic medication | Duration of treatment | Definition of weight gain | Association                                      | NOS score |
|-----------------|------------------|-----------|-------------|-------------|------------------|-------------------|------------------------|--------------------------------|-----------------------|-----------------------|-----------------------------------------------|-----------|
| Reynolds 2002   | China            | Asian     | 123         | 61/62       | 26.6 (7.7)       | SCZ (DSM-IV)      | Yes                    | APDs                            | 10 weeks              | ≥7% BMI change           | T allele has a significant protection effect on weight (p<0.001) | 7         |
| Tsai 2002       | China            | Asian     | 80          | 52/28       | 36.7 (8.4)       | SCZ (DSM-IV)      | NA                     | AAPs                            | 4 months              | ≥7% BMI change           | NS                                                            | 7         |
| Zhang 2002      | China            | Asian     | 117         | 58/59       | 26(8)            | First-episode SCZ | No                     | APDs                            | 10 weeks              | ≥7% weight change        | T allele has a significant protection effect on weight (p<0.001) | 8         |
| Theisen 2004    | Germany          | Caucasian | 97          | 57/40       | 22.1 (7.7)       | SCZ (CCMD-II-R)   | Yes                    | AAPs                            | 12 weeks              | ≥7% BMI change           | NS                                                            | 8         |
| Ellingrod 2005  | USA              | Caucasian | 42          | 34/8        | NA               | SCZ (DSM-IV)      | NA                     | AAPs                            | 6 weeks               | ≥10% BMI change          | T allele has a significant protection effect on weight (p<0.004) | 7         |
| Miller 2005     | USA              | Caucasian | 41          | 26/15       | 35.6 (8.7)       | Treatment-resistant SCZ (DSM-IV) | Yes                    | AAPs                            | 6 months              | ≥7% BMI change           | T allele has a significant protection effect on weight (p<0.003) | 8         |
| Templeman 2005  | Spain            | Caucasian | 73          | 55/18       | 25.2 (9.78)      | First-episode SCZ | No                     | APDs                            | 9 months              | 7% BMI change            | T allele has a significant protection effect on weight (p<0.01) | 8         |
| Ryu 2007        | Korea            | Asian     | 84          | 39/45       | 30.1 (7.4)       | First-episode SCZ | Mostly had            | APDs                            | 4 weeks               | ≥7% BMI change           | T allele has a significant protection effect on weight (p<0.048) | 7         |
| Kuzman 2008     | Croatia          | Caucasian | 108         | 0/108       | 30.6 (11.5)      | SCZ, SCA (DSM-IV) | Not taken or eluted   | AAPs                            | 4 months              | ≥7% weight gain          | NS                                                            | 8         |
| Park 2008       | Korea            | Asian     | 79          | 53/26       | 46.1 (12.1)      | SCZ, SCA (DSM-IV) | Not taken             | AAPs                            | ≥3 months             | ≥7% weight gain          | NS                                                            | 8         |
| Shao 2008       | China            | Asian     | 170         | 60/110      | 23.1 (5.1)       | First-episode SCZ | No                     | APDs                            | Varies                | ≥7% weight gain          | T allele has a significant protection effect on weight (p<0.001) | 8         |
| Godlewska 2009  | Poland           | Caucasian | 107         | 53/54       | 29.3 (10)        | SCZ (DSM-IV-TR)   | Not taken             | AAPs                            | 6 weeks               | ≥10% BMI change          | T allele has a significant protection effect on weight (p=0.002) | 9         |
| Oppen-Rhein 2009| Germany          | Caucasian | 126         | 79/47       | 38.6 (12)        | SCZ, SCA (DSM-IV) | Not taken             | AAPs                            | 6 weeks               | ≥7% weight gain          | T allele has a tendency of protection effect on weight (p<0.063) | 8         |
| Sicard 2010     | Germany and North America | Caucasian | 201         | 138/63      | 35.9 (10.1)      | SCZ, SCA (DSM-IV)  | Yes                   | APDs                            | 10 weeks              | ≥7% weight gain          | NS                                                            | 7         |

Continued
RESULTS

Results of search

A total of 374 studies were found, including 319 studies from the English databases and 55 studies from the Chinese databases. After removing duplicated articles, 249 studies remained. Irrelevant studies were subsequently screened based on titles and abstracts and 34 remained. After reviewing full-text articles, 17 of the 34 studies were excluded. Among the 17 studies, 16 of them had incomplete data\(^ {22-37}\), one of them employed a repeated sample.\(^ {26}\) In the end, 17 articles were included in this meta-analysis (figure 1).

Characteristics of eligible studies

In total, of the 17 studies included in this meta-analysis, 8 of them were studies of Asians\(^ {10\,11\,15\,16\,19\,20\,39\,40}\), including 1696 patients, and 9 were Caucasian\(^ {7\,12-14\,17\,18\,21\,41\,42}\), including 1474 patients. Nine of the studies provide gender group data,\(^ {7\,11\,16\,18-21\,40\,41}\) and seven of the nine studies provide data that could be used for calculating allele frequencies.\(^ {7\,11\,16\,18\,19\,20\,42}\) The NOS scores of the eligible studies were distributed between 7 and 9, indicating their relatively high quality. We divided patients into the ADP and AAP groups as different types of antipsychotic medication. The antipsychotic treatments administered in the ADP group consisted of typical antipsychotics (TAPs) or combined with AAPs; nevertheless, patients of the AAP group received monotherapy with AAPs; nevertheless, patients of the AAP group received monotherapy with AAPs. Details are shown in table 1.

Meta-analysis results

There is heterogeneity among the eligible studies (\(I^2=67.9\%, p_{\text{het}}<0.001\)); therefore, a random-effect model was used to combine the data. The meta-analysis result showed that there is a significant correlation (CT/TT/T vs CC/C: OR 0.34, 95% CI: 0.20 to 0.57, \(z=4.11, p<0.001\)) between the HTR2C-759C/T polymorphism and AIWG in patients with schizophrenia; the patients with T allele on -759 C/T (CT/TT/T) are less likely to gain weight.

We then performed subgroup analyses to evaluate the effect of ethnicity, type of antipsychotic medication and gender. As for ethnicity, we found that patients with T allele are not prone to experience AIWG, whether they are Caucasian (CT/TT/T vs CC/C: OR 0.33, 95% CI: 0.14 to 0.77, \(z=2.55, p=0.011\)) or Asian (CT/TT/T vs CC/C: OR 0.31, 95% CI: 0.18 to 0.52, \(z=4.46, p<0.001\)). In addition, it is worth mentioning the heterogeneity results—the European population subgroup is highly heterogeneous (\(I^2=75.2\%, p_{\text{het}}<0.001\)) while the heterogeneity of the Asian population is not significant (\(I^2=38\%, p_{\text{het}}=0.127\)) (figure 2).

As for the type of antipsychotic medication, the patients were divided into the ADP and AAP groups, and the results showed that the -759C/T polymorphism is significantly correlated with AIWG in both the population that received ADPs (CT/TT/T vs CC/C: OR 0.63, 95% CI: 0.40 to 1.00, \(z=1.97, p=0.049\)) and the population that received AAPs (CT/TT/T vs CC/C: OR 0.21, 95% CI: 0.12-0.33, \(z=4.05, p<0.001\)) (figure 3).
Chen Y, et al. General Psychiatry 2020;33:e100192. doi:10.1136/gpsych-2020-100192

Figure 2  Meta-analysis forest plot of the genetic correlation of HTR2C-759C/T polymorphism and antipsychotic-induced weight gain (subgroup analysis based on ethnicity).

0.09 to 0.47, $z=3.83$, $p<0.001$). The results of the heterogeneity test suggested that the AAP subgroup population is highly heterogeneous ($I^2=74.8\%, p_{h}<0.001$), whereas the ADP subgroup has insignificant heterogeneity ($I^2=14.4\%, p_{h}=0.320$) (figure 3).

It is noteworthy that $HTR2C$ is located on chromosome X; of the included studies in this meta-analysis, nine studies provide gender group data and only seven studies provide data that could be used for calculating allele frequencies. The results demonstrated that the $HTR2C$-$759C/T$ polymorphism is significantly correlated with AIWG in both the male and female populations. However, there was no statistical significance in the result of allele analysis. Details are shown in table 2.

Heterogeneity analysis and sensitivity analysis

The result of the heterogeneity test ($I^2=67.9\%, p_{h}<0.001$) has suggested that there is significant heterogeneity among the included studies. Meta-regression was performed to further explore the source of heterogeneity, and potential confounding variables included population (Asia, America, Europe or mixed samples), type of antipsychotic medication (APDs or AAPS), publication year, sample size, definition of weight gain (7% increase in body weight/body mass index (BMI) or 10% increase in body weight/BMI) and NOS score. It is found that the American population ($t=-1.88$, $p=0.079$; corrected $R^2=17.13\%$) and type of antipsychotic medication ($t=-1.94$, $p=0.071$; corrected $R^2=17.69\%$) might be the main sources of heterogeneity, which can explain 17.13% and 17.69% of heterogeneity, respectively. Inserting each study to meta-regression, we found that the study of Kuzman et al.42 is the main source of heterogeneity ($t=2.26$, $p=0.018$; corrected $R^2=47.45\%$), which can explain 47.75% of heterogeneity.

In terms of the sensitivity analysis, we conducted the analysis by excluding one included study at a time to determine the impact of each study on the combined effect size (figure 4). The result showed that the Kuzman 2008 study has a great effect on OR value and its 95% CI,
Chen Y, et al. General Psychiatry 2020;33:e100192. doi:10.1136/gpsych-2020-100192

Figure 3  Meta-analysis forest plot of the genetic association between HTR2C-759C/T polymorphism and antipsychotic-induced weight gain (subgroup analysis based on the type of antipsychotic medication). AAP, atypical antipsychotic drug; APD, antipsychotic drug.

Further validating that the Kuzman 2008 study was the main source of heterogeneity of this meta-analysis. However, this study had not affected the final direction of the results, so the results of this meta-analysis are relatively stable.

Publication bias
Publication bias is roughly determined by Begg's funnel plot (figure 5) and identified quantitatively by the combination of Begg's rank correlation test and Egger's regression test. Begg's funnel plot showed that the distribution of each study is not completely symmetrical, suggesting the possibility of publication bias. The result

Table 2  Results of allele analysis and the subgroup analysis based on gender

| Model         | OR   | 95% CI          | P value | I² (%) |
|---------------|------|-----------------|---------|--------|
| Allele T vs C | 0.58 | 0.30 to 1.12    | 0.104   | 78.30  |
| Male T vs C   | 0.45 | 0.20 to 1.00    | 0.049   | 47.50  |
| Female CT/TT vs CC | 0.34 | 0.14 to 0.80 | 0.013   | 73.60  |

Figure 4  Sensitivity analysis.
protection effect, 2 studies showed that T allele had a significant weight gain. However, there was overlapping in the CIs of the two groups, indicating that there is no statistical significance despite the difference in tendency of the influence magnitude of the -759C/T polymorphism on AIWG between the two groups.

Owing to the influence of chromosomes, hormones and different living habits, the occurrence and characteristics of metabolic-related diseases such as weight gain have gender differences. Furthermore, the HTR2C gene is located on chromosome X; it is necessary to perform a subgroup analysis of gender stratification. Nevertheless, the provision of related data in the included studies is limited, the total sample size is relatively insufficient and the heterogeneity is high. Although the analyses results showed significant correlation between the HTR2C-759C/T polymorphism and AIWG in the male and female populations, and the T allele has a stronger protective effect on weight gain in the female population than the male population, the authenticity is still uncertain. For the possible association with few included data, the allele analysis had not shown significant results.

Generally, this meta-analysis has suggested that a significant association between the HTR2C-759C/T polymorphism and AIWG. The T allele of HTR2C-759C/T polymorphism has a protective effect on AIWG. Although the heterogeneity test showed that the included studies are of high heterogeneity, the sensitivity analysis and publication bias showed that the results of this study were relatively stable and have no significant publication bias.

Limitation
Our meta-analysis must be interpreted with some limitations. First, we use ORs for the estimation of effect size, only including the literature that provided the quantity or proportion of patients with a significant increase on weight or BMI in each genotype group, but not the literature that merely provided specific weight gain data. Although an OR is more clinically meaningful than the standard mean difference, it is undeniable that we have abandoned a lot of meaningful clinical data, resulting in a decrease in the number of included studies and a reduction in the effectiveness of the tests. Second, regarding the publication bias, the relevant results show that the publication bias is not significant, but it still exists, and some negative results may not have been published. In addition, the studies we have included were publicly published and the language is either Chinese or English. This may lead to the omission of relevant literature published in countries in which the native language is not Chinese or English, causing certain biases.

Implications
AIWG is a rigorous problem in the treatment of schizophrenia, and there is still not an effective way to reverse AIWG. In response to this situation, conducting genetic research on AIWG is of great significance for identifying
the high-risk population so as to guide them in drug selection. In addition, the eventual result direction aligns by comparing this article with the previous meta-analysis, suggesting a significant association between the HTR2C-759C/T polymorphism and AIWG and a protective effect of the T allele against AIWG. In comparison with the previous meta-analyses, this article supplements a lot of Chinese research, and the included studies were more comprehensive, with a larger total sample size and higher power of test.

Contributors
YC contributed to the literature search; YC, Y-WW and X-YF contributed to literature screening and data extraction; YC, YZ and L-SS contributed to statistical analysis and writing of this paper; and CZ contributed to the planning and guidance of this paper.

Funding
This study was funded by National Natural Science Foundation of China (81717450); Science and Technology Commission of Shanghai Municipality (2015040029).

Competing interests
None declared.

Patient consent for publication
Not required.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
No additional unpublished data are available.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Yan Chen http://orcid.org/0000-0002-9296-7491

REFERENCES
1 Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry 2007;68:e04.
2 Raben AT, Marsha VS, Chintoh A, et al. The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment. Front Neurol 2017;11:741.
3 Jeon SW, Kim Y-K. Unresolved issues for utilization of atypical antipsychotics in schizophrenia: antipsychotic polypharmacy and metabolic syndrome. Int J Mol Sci 2017;18:2174.
4 Puangpetch A, Umanasa W, Umanana N, et al. Genetic polymorphisms of HTR2C, Lep and Lepr in patients treated with atypical antipsychotic drugs. J Pharm Pharmacol 2018;70:536–42.
5 Blundell JE. Is this a role for serotonin (5-hydroxytryptamine) in feeding? Int J Obes 1977;1:15–42.
6 Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1996;374:542–6.
7 Sidar SN, Zai CC, Tiwari AK, et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics J 2010;11:561–71.
8 Ma X, Maimaitiexitai T, Zhang R, et al. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. Int J Psychiatr Clin Pract 2014;18:229–42.
9 Wells GA, Shea B, O’Connell D, et al. The Newcastle-OTTawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis, 2011. Available: www.ohri.ca/programs/clinical_epidemiology/oxford.asp [Accessed 25 Mar 2019].
10 Reynolds GP, Zhang Z-J, Zhang X-B. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002;359:2086–7.
11 Zhang Z, Zhang X, Yao Z, et al. Association of antipsychotic agent-induced weight gain with a polymorphism of the promoter region of the 5-HT2C receptor gene. Zhonghua Yi Xue Za Zhi 2002;82:1097–101. Chinese.
12 Ellingson VL, Perry PJ, Ringold JC, et al. Weight gain associated with the −759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005;134B:76–8.
13 Miller DD, Ellingson VL, Holman TL, et al. Clozapine-induced weight gain associated with the 5-HT2C receptor −759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005;133B:97–100.
14 Templeman LA, Reynolds GP, Arranz B, et al. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2006;15:185–200.
15 Ruo S, Cho EY, Park T, et al. −759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog Neuropsychopharmac Biol Psychiatry 2007;31:673–7.
16 Shao P, Zhao J-ping, Chen J-dong, et al. [Association of HTR2C-759C/T and −697G/C polymorphisms with antipsychotic agent-induced weight gain]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008;33:312–5. Chinese.
17 Godlewksa BR, Olajossy-Hilkesberger L, Ciwniuk M, et al. Olanzapine-induced weight gain is associated with the −759C/T and −697G/C polymorphisms of the HTR2C gene. Pharmacogenomics J 2009;9:234–41.
18 Oppe-Rhein C, Brandl EJ, Müller DJ, et al. Association of HTR2C, but not Lep or INS1G2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics 2010;11:1773–80.
19 Liu WZ, HB H, ZY H, et al. Study of the association between olanzapine-induced weight gain and the −759C/T polymorphism of HTR2C gene. Zhong Shao Yi Xue 2011;39:1572–5.
20 Keng SH, Lee J-I, Han HR, et al. Polymorphisms of the leptin and HTR2C genes and clozapine-induced weight change and baseline BMI in patients with chronic schizophrenia. Psychiatr Res 2014;242:249–56.
21 Daray FM, Rodante D, Carosella LG, et al. −759C/T Polymorphism of the HTR2C gene is associated with second generation antipsychotic-induced weight gain in female patients with schizophrenia. Pharmacopsychiatry 2017;50:14–18.
22 Basile VS, Masellis M, De Luca V, et al. 759C/T genetic variation of 5HT2C receptor and clozapine-induced weight gain. Lancet 2002;360:1799–801.
23 Grīdiniāna RC, Andreescu NJ, Nussbauma LA, et al. −759C/T polymorphism of the HTR2C gene is not correlated with atypical antipsychotics-induced weight gain, among Romanian psychotic patients. Rom J Morphol Embryol 2016;57:1343–9.
24 Houston JP, Kohler J, Bishop JR, et al. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J Clin Psychiatry 2012;73:1077–86.
25 Kuzman MR, Medved V, Bozina N, et al. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogenomics J 2011;11:33–44.
26 Laika B, Leucht S, Heres S, et al. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 2010;10:20–9.
27 Lane H-Y, Liu Y-C, Huang C-L, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychiatry 2006;67:128–34.
28 Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003;160:677–9.
29 Thompson A, Lavedan C, Volpi S. Absence of weight gain association with the HTR2C −759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res 2010;175:271–3.
30 Uijke H, Nomura A, Morita Y, et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry 2008;69:1416–22.
31 Al-Janabi I, Arranz MJ, Blakemore AIF, et al. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatry Gen 2010;17:203.
32 Gregoor JG, Mulder H, Cohen D, et al. Combined HTR2C-LEP genotype as a determinant of obesity in patients using antipsychotic medication. J Clin Psychopharmacol 2010;30:702–5.
33 Gunes A, Melkersson KI, Scorza MG, et al. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol 2009;29:65–8.
34 Mulder H, Cohen D, Scheffer H, et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol 2009;29:16–20.
35 Yevtushenko OO, Cooper SJ, O’Neill R, et al. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug
Dr. Chen Yan obtained a bachelor’s degree from Wenzhou Medical University, Zhejiang Province, China in 2017. Since then she has been working as a postgraduate student at the Shanghai Mental Health Center, Shanghai jiao Tong University School of Medicine. Her main research interest includes schizophrenia.